Greenwich LifeSciences, Inc.
GLSI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $135,732 | $121,275 | $125,657 | $147,705 |
| - Cash | $3,807 | $3,125 | $2,750 | $4,092 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $131,925 | $118,150 | $122,907 | $143,613 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| EBITDA | -$4,152 | -$4,045 | -$3,281 | -$8,039 |
| % Margin | – | – | – | – |
| Net Income | -$4,152 | -$4,025 | -$3,258 | -$8,040 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.3 | -0.3 | -0.25 | -0.61 |
| % Growth | 0% | -20% | 59% | – |
| Operating Cash Flow | -$2,671 | -$2,233 | -$1,834 | -$1,852 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$2,671 | -$2,233 | -$1,834 | -$1,852 |